Alliance for Regenerative Medicine: Stem Cells 2014

Presented by: Teresa Leezer, CEO
RhinoCyte, Inc. is a privately owned biopharmaceutical company focused on developing transformational technologies that will change the way neurodegenerative disorders are treated. Founded in 2005, the Company is advancing innovative treatment paradigms that leverage proprietary cell therapies for high unmet clinical needs including Spinal Cord Injury (SCI), Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS) Multiple Sclerosis (MS) and Type 1 Diabetes. RhinoCyte leverages novel regenerative therapies to extend and enhance the quality of human life without immunosuppression or genetic manipulation.

Presented by: Martin McGlynn, President & CEO
StemCells, Inc. is engaged in research and clinical development of cell-based therapeutics using the Company’s platform technology, a proprietary highly purified population of human neural stem cells, HuCNS-SC® cells. The Company is developing therapies for central nervous system disorders. The Company completed enrollment in a Phase I/II clinical trial in spinal cord injury and has reported positive data for the first eight patients. The Company is also conducting a Phase I/II clinical trial in dry age-related macular degeneration (AMD). Both studies release final results next year. StemCells, Inc. is pursuing preclinical studies in Alzheimer’s disease with funding support from the California Institute of Regenerative Medicine (CIRM). In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal childhood myelination disorder, the Company showed preliminary evidence of donor-derived myelination in all four patients. StemCells, Inc. also markets stem cell research products including media and reagents under the SC Proven® brand.

Presented by: Tom Ulich, M.D., Chief Scientific Officer
InVivo Therapeutics is a pioneering biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The Company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD., Professor at Massachusetts Institute of Technology (MIT), and Joseph Vacanti, M.D., who is affiliated with Massachusetts General Hospital. InVivo is developing biocompatible neuro-spinal scaffolds to treat acute SCI and neuro-spinal scaffolds plus stem cells to treat chronic SCI. Data on InVivo’s scaffold and scaffold plus stem cells technology was first published in the Proceedings of the National Academy of Sciences (PNAS) in 2002 and has since been demonstrated to successfully promote functional recovery following traumatic spinal cord injury in several models. Data from InVivo’s pilot non-human primate study was published in the Journal of Neuroscience Methods in 2010, which earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine.

Presented by: Jane Lebkowski, Ph.D., President of R&D
Asterias Biotherapeutics is developing therapies based on pluripotent stem cells to treat diseases or injuries having major unmet needs. Asterias’ initial focus is on two clinical stage programs including oligodendrocyte progenitor cells (AST-OPC1) for spinal cord injuries and antigen-presenting allogeneic dendritic cells (AST-VAC2) for lung cancer. In October of 2013, Asterias acquired the cell therapy assets of Geron Corporation. These assets included INDs for the clinical stage AST-OPC1 and AST-VAC1 programs, banks of cGMP-manufactured AST-OPC1 drug product, cGMP master and working cell banks of human embryonic stem cells. They also included over 400 patents and patent applications filed worldwide including broad issued claims to fundamental platform technologies for the scalable growth of pluripotent stem cells and compositions of matter for several hESC-derived therapeutic cell types, research cell banks, customized reagents and equipment, and various assets relating to the AST-VAC2 program and preclinical programs in cardiology and orthopedics.

This entry was posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, spinal cord injury research, Stem Cell Research and tagged , , , , . Bookmark the permalink.